Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine

Area of Science:

• Pediatrics
• Immunology
• Vaccinology

Background:

• Pneumococcal conjugate vaccines (PCV) are crucial for reducing childhood pneumonia and meningitis.
• Resource-limited countries require cost-effective infant vaccination strategies.

Purpose of the Study:

• To determine the optimal infant pneumococcal vaccination schedule for resource-limited settings.
• To evaluate the immunogenicity of varying doses of 7-valent PCV in Fijian infants.

Main Methods:

• Infants received 0, 1, 2, or 3 doses of 7-valent PCV.
• Antibody levels (geometric mean concentration - GMC) were measured at 18 weeks and 12 months.
• Serological responses were compared across different vaccination groups.

Main Results:

• Three PCV doses induced GMCs >= 1.0 microg/mL for all serotypes.
• Two doses resulted in lower GMCs for serotypes 6B, 14, and 23F compared to three doses.
• A single PCV dose elicited significant responses against all serotypes compared to unvaccinated infants.
• Differences in GMC between two and three doses were minimal by 12 months, except for serotype 14.

Conclusions:

• While three PCV doses provide the highest antibody levels, two doses also induce robust immunity.
• A single-dose strategy may offer substantial protection, simplifying infant vaccination in resource-poor settings.
• Further research could explore the long-term efficacy and cost-effectiveness of reduced PCV dosing schedules.